DHR vs. SNY: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at DHR and SNY, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
DHR is a standard domestic listing, while SNY trades as an American Depositary Receipt (ADR), offering U.S. investors access to its foreign-listed shares.
| Symbol | DHR | SNY |
|---|---|---|
| Company Name | Danaher Corporation | Sanofi |
| Country | United States | France |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Life Sciences Tools & Services | Pharmaceuticals |
| Market Capitalization | 158.33 billion USD | 127.74 billion USD |
| Exchange | NYSE | NasdaqGS |
| Listing Date | December 29, 1978 | July 1, 2002 |
| Security Type | Common Stock | ADR |
Historical Performance
This chart compares the performance of DHR and SNY by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | DHR | SNY |
|---|---|---|
| 5-Day Price Return | 4.75% | 0.94% |
| 13-Week Price Return | 4.87% | 3.93% |
| 26-Week Price Return | 12.51% | -3.88% |
| 52-Week Price Return | -8.41% | -1.08% |
| Month-to-Date Return | 2.71% | 2.61% |
| Year-to-Date Return | -3.63% | -4.11% |
| 10-Day Avg. Volume | 3.63M | 1.47M |
| 3-Month Avg. Volume | 4.17M | 1.85M |
| 3-Month Volatility | 31.75% | 28.76% |
| Beta | 0.90 | 1.08 |
Profitability
Return on Equity (TTM)
DHR
6.88%
Life Sciences Tools & Services Industry
- Max
- 23.81%
- Q3
- 11.79%
- Median
- 7.51%
- Q1
- 3.14%
- Min
- -6.95%
DHR’s Return on Equity of 6.88% is on par with the norm for the Life Sciences Tools & Services industry, indicating its profitability relative to shareholder equity is typical for the sector.
SNY
18.76%
Pharmaceuticals Industry
- Max
- 38.95%
- Q3
- 20.34%
- Median
- 11.59%
- Q1
- 3.32%
- Min
- -10.91%
SNY’s Return on Equity of 18.76% is on par with the norm for the Pharmaceuticals industry, indicating its profitability relative to shareholder equity is typical for the sector.
Net Profit Margin (TTM)
DHR
14.43%
Life Sciences Tools & Services Industry
- Max
- 33.77%
- Q3
- 17.97%
- Median
- 8.97%
- Q1
- 3.80%
- Min
- -11.89%
DHR’s Net Profit Margin of 14.43% is aligned with the median group of its peers in the Life Sciences Tools & Services industry. This indicates its ability to convert revenue into profit is typical for the sector.
SNY
20.66%
Pharmaceuticals Industry
- Max
- 39.07%
- Q3
- 19.28%
- Median
- 13.48%
- Q1
- 5.73%
- Min
- -8.86%
A Net Profit Margin of 20.66% places SNY in the upper quartile for the Pharmaceuticals industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin (TTM)
DHR
19.05%
Life Sciences Tools & Services Industry
- Max
- 31.55%
- Q3
- 21.26%
- Median
- 14.06%
- Q1
- 8.54%
- Min
- 0.11%
DHR’s Operating Profit Margin of 19.05% is around the midpoint for the Life Sciences Tools & Services industry, indicating that its efficiency in managing core business operations is typical for the sector.
SNY
20.74%
Pharmaceuticals Industry
- Max
- 45.58%
- Q3
- 24.35%
- Median
- 18.05%
- Q1
- 7.58%
- Min
- -11.88%
SNY’s Operating Profit Margin of 20.74% is around the midpoint for the Pharmaceuticals industry, indicating that its efficiency in managing core business operations is typical for the sector.
Profitability at a Glance
| Symbol | DHR | SNY |
|---|---|---|
| Return on Equity (TTM) | 6.88% | 18.76% |
| Return on Assets (TTM) | 4.40% | 10.65% |
| Net Profit Margin (TTM) | 14.43% | 20.66% |
| Operating Profit Margin (TTM) | 19.05% | 20.74% |
| Gross Profit Margin (TTM) | 59.59% | 72.29% |
Financial Strength
Current Ratio (MRQ)
DHR
1.52
Life Sciences Tools & Services Industry
- Max
- 4.76
- Q3
- 2.87
- Median
- 1.75
- Q1
- 1.37
- Min
- 0.57
DHR’s Current Ratio of 1.52 aligns with the median group of the Life Sciences Tools & Services industry, indicating that its short-term liquidity is in line with its sector peers.
SNY
1.06
Pharmaceuticals Industry
- Max
- 5.45
- Q3
- 2.99
- Median
- 1.98
- Q1
- 1.29
- Min
- 0.78
SNY’s Current Ratio of 1.06 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
Debt-to-Equity Ratio (MRQ)
DHR
0.33
Life Sciences Tools & Services Industry
- Max
- 0.95
- Q3
- 0.70
- Median
- 0.45
- Q1
- 0.18
- Min
- 0.00
DHR’s Debt-to-Equity Ratio of 0.33 is typical for the Life Sciences Tools & Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
SNY
0.30
Pharmaceuticals Industry
- Max
- 1.79
- Q3
- 0.78
- Median
- 0.31
- Q1
- 0.08
- Min
- 0.00
SNY’s Debt-to-Equity Ratio of 0.30 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
DHR
22.31
Life Sciences Tools & Services Industry
- Max
- 45.00
- Q3
- 27.84
- Median
- 7.16
- Q1
- 2.12
- Min
- -14.08
DHR’s Interest Coverage Ratio of 22.31 is positioned comfortably within the norm for the Life Sciences Tools & Services industry, indicating a standard and healthy capacity to cover its interest payments.
SNY
22.06
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 43.60
- Median
- 10.15
- Q1
- 2.37
- Min
- -42.71
SNY’s Interest Coverage Ratio of 22.06 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | DHR | SNY |
|---|---|---|
| Current Ratio (MRQ) | 1.52 | 1.06 |
| Quick Ratio (MRQ) | 0.98 | 0.30 |
| Debt-to-Equity Ratio (MRQ) | 0.33 | 0.30 |
| Interest Coverage Ratio (TTM) | 22.31 | 22.06 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
DHR
0.54%
Life Sciences Tools & Services Industry
- Max
- 1.02%
- Q3
- 0.67%
- Median
- 0.32%
- Q1
- 0.00%
- Min
- 0.00%
DHR’s Dividend Yield of 0.54% is consistent with its peers in the Life Sciences Tools & Services industry, providing a dividend return that is standard for its sector.
SNY
4.40%
Pharmaceuticals Industry
- Max
- 6.72%
- Q3
- 3.48%
- Median
- 1.90%
- Q1
- 0.00%
- Min
- 0.00%
With a Dividend Yield of 4.40%, SNY offers a more attractive income stream than most of its peers in the Pharmaceuticals industry, signaling a strong commitment to shareholder returns.
Dividend Payout Ratio (TTM)
DHR
24.18%
Life Sciences Tools & Services Industry
- Max
- 97.67%
- Q3
- 61.34%
- Median
- 18.53%
- Q1
- 0.00%
- Min
- 0.00%
DHR’s Dividend Payout Ratio of 24.18% is within the typical range for the Life Sciences Tools & Services industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
SNY
52.56%
Pharmaceuticals Industry
- Max
- 199.58%
- Q3
- 85.87%
- Median
- 49.36%
- Q1
- 1.12%
- Min
- 0.00%
SNY’s Dividend Payout Ratio of 52.56% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
Dividend at a Glance
| Symbol | DHR | SNY |
|---|---|---|
| Dividend Yield (TTM) | 0.54% | 4.40% |
| Dividend Payout Ratio (TTM) | 24.18% | 52.56% |
Valuation
Price-to-Earnings Ratio (TTM)
DHR
44.62
Life Sciences Tools & Services Industry
- Max
- 78.22
- Q3
- 57.42
- Median
- 34.18
- Q1
- 28.39
- Min
- 1.55
DHR’s P/E Ratio of 44.62 is within the middle range for the Life Sciences Tools & Services industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
SNY
7.90
Pharmaceuticals Industry
- Max
- 52.64
- Q3
- 29.89
- Median
- 20.77
- Q1
- 13.37
- Min
- 5.71
In the lower quartile for the Pharmaceuticals industry, SNY’s P/E Ratio of 7.90 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
Price-to-Sales Ratio (TTM)
DHR
6.44
Life Sciences Tools & Services Industry
- Max
- 10.69
- Q3
- 6.37
- Median
- 4.95
- Q1
- 3.27
- Min
- 1.04
DHR’s P/S Ratio of 6.44 is in the upper echelon for the Life Sciences Tools & Services industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.
SNY
1.63
Pharmaceuticals Industry
- Max
- 8.74
- Q3
- 4.66
- Median
- 2.37
- Q1
- 1.67
- Min
- 0.11
In the lower quartile for the Pharmaceuticals industry, SNY’s P/S Ratio of 1.63 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
Price-to-Book Ratio (MRQ)
DHR
2.59
Life Sciences Tools & Services Industry
- Max
- 8.12
- Q3
- 5.04
- Median
- 3.94
- Q1
- 2.12
- Min
- 1.13
DHR’s P/B Ratio of 2.59 is within the conventional range for the Life Sciences Tools & Services industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
SNY
1.32
Pharmaceuticals Industry
- Max
- 9.86
- Q3
- 5.28
- Median
- 2.48
- Q1
- 1.57
- Min
- 0.59
SNY’s P/B Ratio of 1.32 is in the lower quartile for the Pharmaceuticals industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
Valuation at a Glance
| Symbol | DHR | SNY |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 44.62 | 7.90 |
| Price-to-Sales Ratio (TTM) | 6.44 | 1.63 |
| Price-to-Book Ratio (MRQ) | 2.59 | 1.32 |
| Price-to-Free Cash Flow Ratio (TTM) | 31.16 | 10.85 |